Identification of CD5/Cyclin D1 Double-negative Pleomorphic Mantle Cell Lymphoma: A Clinicopathologic, Genetic, and Gene Expression Study.

Szczegóły
Abstrakt

Tytuł:: Identification of CD5/Cyclin D1 Double-negative Pleomorphic Mantle Cell Lymphoma: A Clinicopathologic, Genetic, and Gene Expression Study.
Autorzy:: Chuang WY; Department of Pathology.; Graduate Institute of Clinical Medical Sciences, College of Medicine.
Chang ST; Department of Pathology, Chi-Mei Medical Center.; Department of Nursing, National Tainan Institute of Nursing, Tainan.
Yuan CT; Department of Pathology, National Taiwan University Hospital, College of Medicine, National Taiwan University.
Chang GJ; Graduate Institute of Clinical Medical Sciences, College of Medicine.
Chang H; Department of Internal Medicine, Division of Hematology and Oncology.
Yeh CJ; Department of Pathology.
Ueng SH; Department of Pathology.
Kao HW; Department of Internal Medicine, Division of Hematology and Oncology.
Wang TH; Tissue Bank.
Wan YL; Department of Medical Imaging and Intervention, Chang Gung Memorial Hospital.
Shih LY; Department of Internal Medicine, Division of Hematology and Oncology.
Chuang SS; Department of Pathology, Chi-Mei Medical Center.; Department of Pathology, School of Medicine, Taipei Medical University and National Taiwan University, Taipei, Taiwan.
Hsueh C; Department of Pathology.; Tissue Bank.; Chang Gung Molecular Medicine Research Center, Chang Gung University, Taoyuan.
Źródło:: The American journal of surgical pathology [Am J Surg Pathol] 2020 Feb; Vol. 44 (2), pp. 232-240.
Typ publikacji:: Case Reports; Journal Article; Research Support, Non-U.S. Gov't
Język:: English
Imprint Name(s):: Publication: <2015- > : Philadelphia, PA : Wolters Kluwer Health, Inc.
Original Publication: New York, Masson.
MeSH Terms:: Gene Expression Regulation, Neoplastic*
Biomarkers, Tumor/*metabolism
CD5 Antigens/*metabolism
Cyclin D1/*metabolism
Lymphoma, Large B-Cell, Diffuse/*diagnosis
Lymphoma, Mantle-Cell/*diagnosis
SOXC Transcription Factors/*metabolism
Adult ; Aged ; Aged, 80 and over ; Biomarkers, Tumor/genetics ; CD5 Antigens/genetics ; Cyclin D1/genetics ; Diagnosis, Differential ; Gene Expression Profiling ; Humans ; Immunohistochemistry ; In Situ Hybridization, Fluorescence ; Lymphoma, Large B-Cell, Diffuse/genetics ; Lymphoma, Large B-Cell, Diffuse/pathology ; Lymphoma, Mantle-Cell/genetics ; Lymphoma, Mantle-Cell/pathology ; Male ; Middle Aged ; Phenotype ; SOXC Transcription Factors/genetics
References:: Swerdlow SH, Campo E, Seto M, et alSwerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J. Mantle cell lymphoma. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2017:285–290.
Cook JR, Swerdlow SHOrazi A, Weiss LM, Foucar K, Knowles DM. Mantle cell lymphoma. Knowles’ Neoplastic Hematopathology. Philadelphia, PA: Lippincott Williams & Wilkins; 2014:456–469.
Liu Z, Dong HY, Gorczyca W, et al. CD5− mantle cell lymphoma. Am J Clin Pathol. 2002;118:216–224.
Chuang WY, Chang H, Chang GJ, et al. Pleomorphic mantle cell lymphoma morphologically mimicking diffuse large B cell lymphoma: common cyclin D1 negativity and a simple immunohistochemical algorithm to avoid the diagnostic pitfall. Histopathology. 2017;70:986–999.
Fu K, Weisenburger DD, Greiner TC, et al. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood. 2005;106:4315–4321.
Martin-Garcia D, Navarro A, Valdes-Mas R, et al. CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1(−) mantle cell lymphoma. Blood. 2019;133:940–951.
Bhattaram P, Penzo-Mendez A, Sock E, et al. Organogenesis relies on SoxC transcription factors for the survival of neural and mesenchymal progenitors. Nat Commun. 2010;1:9.
Mozos A, Royo C, Hartmann E, et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica. 2009;94:1555–1562.
Zeng W, Fu K, Quintanilla-Fend L, et al. Cyclin D1-negative blastoid mantle cell lymphoma identified by SOX11 expression. Am J Surg Pathol. 2012;36:214–219.
Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–3068.
Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res. 2009;15:5494–5502.
Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275–282.
Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30:3452–3459.
Chuang WY, Chang H, Shih LY, et al. CD5 positivity is an independent adverse prognostic factor in elderly patients with diffuse large B cell lymphoma. Virchows Arch. 2015;467:571–582.
Scott DW, Wright GW, Williams PM, et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood. 2014;123:1214–1217.
Babicki S, Arndt D, Marcu A, et al. Heatmapper: web-enabled heat mapping for all. Nucleic Acids Res. 2016;44:W147–W153.
Campo E, Jares PJaffe ES, Arber DA, Campo E, Harris NL, Quintanilla-Martinez L. Mantle cell lymphoma. Hematopathology. Philadelphia, PA: Elsevier; 2017:397–414.
Nakashima MO, Durkin L, Bodo J, et al. Utility and diagnostic pitfalls of SOX11 monoclonal antibodies in mantle cell lymphoma and other lymphoproliferative disorders. Appl Immunohistochem Mol Morphol. 2014;22:720–727.
Farfsing A, Engel F, Seiffert M, et al. Gene knockdown studies revealed CCDC50 as a candidate gene in mantle cell lymphoma and chronic lymphocytic leukemia. Leukemia. 2009;23:2018–2026.
Psyrri A, Papageorgiou S, Liakata E, et al. Phosphatidylinositol 3′-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma. Clin Cancer Res. 2009;15:5724–5732.
Chen YH, Gao J, Fan G, et al. Nuclear expression of sox11 is highly associated with mantle cell lymphoma but is independent of t(11;14)(q13;q32) in non-mantle cell B-cell neoplasms. Mod Pathol. 2010;23:105–112.
Cortelazzo S, Ferreri A, Hoelzer D, et al. Lymphoblastic lymphoma. Crit Rev Oncol Hematol. 2017;113:304–317.
Leoncini L, Campo E, Stein H, et alSwerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J. Burkitt lymphoma. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2017:330–334.
Foucar K, Falini B, Stein HSwerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J. Hairy cell leukemia. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2017:226–228.
Soldini D, Valera A, Sole C, et al. Assessment of SOX11 expression in routine lymphoma tissue sections: characterization of new monoclonal antibodies for diagnosis of mantle cell lymphoma. Am J Surg Pathol. 2014;38:86–93.
Substance Nomenclature:: 0 (Biomarkers, Tumor)
0 (CCND1 protein, human)
0 (CD5 Antigens)
0 (SOX11 protein, human)
0 (SOXC Transcription Factors)
136601-57-5 (Cyclin D1)
Entry Date(s):: Date Created: 20191106 Date Completed: 20200513 Latest Revision: 20210131
Update Code:: 20240104
DOI:: 10.1097/PAS.0000000000001390
PMID:: 31688139
: Czasopismo naukowe

Pleomorphic mantle cell lymphoma (PMCL) can closely mimic diffuse large B-cell lymphoma (DLBCL) morphologically, and expression of CD5 and cyclin D1 is helpful for differential diagnosis. To date, no cases of CD5/cyclin D1 double-negative PMCL have been reported. Four cases of B-cell lymphoma with an immunophenotype of CD5(-) cyclin D1(-) SOX11(+) and morphologic features compatible with DLBCL were included. Two were previously identified, and the other 2 were screened from 500 cases of B-cell lymphoma. We analyzed their clinicopathologic, immunophenotypic, genetic, and gene expression features. Cases of cyclin D1-positive PMCL, cyclin D1-negative PMCL, germinal center B-cell (GCB) DLBCL, and activated B cell (ABC) DLBCL were also studied for comparison. Similar to other PMCL cases, these 4 patients were mainly elderly male individuals with an aggressive clinical course. None of these tumors had detectable translocations involving CCND1, CCND2, CCND3, CCNE1, CCNE2, MYC, BCL2, or BCL6. The genome-wide copy number profile of these 4 cases was similar to that of cyclin D1-negative PMCL. None of these tumors had high expression of cyclin D1, cyclin D2, or cyclin D3. Similar to cyclin D1-negative PMCL, these cases had higher expression of cyclin E1 and cyclin E2 compared with cyclin D1-positive PMCL. The gene expression pattern of these tumors was also similar to that of cyclin D1-negative PMCL. Here we report for the first time 4 cases of CD5/cyclin D1 double-negative PMCL. SOX11 positivity is useful to identify these rare tumors, and further genetic and gene expression analysis can be used to confirm the diagnosis.

Informacja